Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22579788 | 0.93 | TSHR (0.35) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL20747706 | 0.93 | MAPT (0.41) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL20747629 | 0.92 | MAPT (0.40) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL20969024 | 0.89 | MAPT (0.37) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL20747690 | 0.86 | TSHR (0.37) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL28159607 | 0.86 | MAPT (0.43) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL21757361 | 0.84 | TSHR (0.33) | L3MBTL1ALDH1A1PRKCA | |
| SCHEMBL20747669 | 0.83 | CYP4F2 (0.53) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL10087754 | 0.83 | CYP4F2 (0.53) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL10087756 | 0.83 | CYP4F2 (0.53) | MAPTMEN1KMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | MAPT 3216/4885MEN1 2269/4885KMT2A 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.